Core Points - The company completed the grant registration of the 2025 stock option incentive plan on September 26, 2025, with a total of 1.16 million stock options granted to 13 eligible participants [1][2][7] - The stock options have a maximum validity period of 60 months, with different waiting periods of 12, 24, and 36 months for various grants [2][3] - The exercise price for the stock options is set at 15.05 yuan per option [3] Grant Details - The stock options were granted to 13 individuals, with one participant voluntarily waiving their entitlement [1][2] - The performance assessment for the stock options is based on company revenue and R&D investment rates over the fiscal years 2025 to 2027 [5] - Individual performance assessments will also influence the exercise ratio of the stock options, categorized into five levels: S, A, B, C, D [6] Financial Impact - The company will use the Black-Scholes model to calculate the fair value of the stock options, and adjustments will be made based on the number of exercisable options and performance metrics at each balance sheet date [7][8] - The total expenses related to the stock option incentive will be amortized and finalized based on the annual audit report from the accounting firm [8]

Core Viewpoint - Beijing Wandong Medical Technology Co., Ltd. has completed the registration of its 2025 stock option incentive plan, granting a total of 9.6 million stock options to 85 individuals, with the registration completed on May 30, 2025 [2][11]. Summary by Sections Stock Option Grant Details - The stock option grant date is May 21, 2025, with a total of 9.6 million options granted to 85 individuals at an exercise price of 15.05 yuan per option [6][12]. - The incentive plan is valid for a maximum of 60 months from the grant date, with waiting periods of 12, 24, and 36 months for different portions of the options [7]. Approval Process - The plan underwent several approval steps, including meetings of the board and supervisory committee, public announcements, and shareholder meetings, culminating in the approval at the annual general meeting on April 16, 2025 [3][4]. - The board authorized the handling of the incentive plan's related matters, and the supervisory committee verified the list of incentive recipients [4][11]. Performance Assessment Criteria - The performance assessment for the stock options is based on the company's revenue growth and R&D investment rates over the fiscal years 2025 to 2027, with specific targets set against the 2024 revenue as a baseline [9][10]. - Individual performance assessments will also be conducted, with a grading system from S to D determining the proportion of options that can be exercised [10]. Financial Impact - The company will calculate the fair value of the stock options using the Black-Scholes model, and the expenses related to the stock options will be recognized in accordance with accounting standards [12][13].